GLOSTRUP, DENMARK--(Marketwire - December 14, 2011) -
Dako, a world leader in tissue-based cancer diagnostics, has received
from the US Food and Drug Administration (FDA) to market HER2 CISH
Kit in the United States. This new diagnostic test is specifically
an aid in the assessment of breast cancer patients for whom treatment with
Herceptin® is being considered. It allows pathologists to perform
tests and score the results using readily available bright field
HER2 CISH pharmDx™ Kit from Dako opens the way to molecular testing in
cancer diagnosis for a wider group of pathology laboratories, offering a
of benefits to the pathologists.
"With the FDA approval of HER2 CISH pharmDx™ Kit, Dako has provided
important tool to aid in the selection of therapy for patients diagnosed
breast cancer. The approval of HER2 CISH pharmDx™ Kit provides a welcome
methodology for the evaluation of HER2 status in breast cancer that
the need for fluorescence microscopy. A clear advantage of HER2 CISH
Kit is that the stains are permanent and can be archived for later
says David Hicks, M.D., Director of Surgical Pathology, University of
Medical Center, New York.
Traditionally, molecular testing requires the use of a fluorescence
which is not readily available in all pathology laboratories. With HER2
pharmDx™ Kit, however, the pathologist can use a traditional bright
microscope to determine whether the patient is eligible for treatment with
HER2 CISH pharmDx™ Kit is a dual color test that is generally preferred
compared to single color tests, as both the HER2 gene and Centromere-17
reference signals can be seen on the same slide. The HER2 scoring, which is
supported by a standardized and validated protocol, is considerably faster
a CISH test than with a FISH test. Moreover, with HER2 CISH pharmDx™
test slides can be stored for re-evaluation.
"I am happy to announce the FDA approval of HER2 CISH pharmDx™ Kit. We
seen how other Dako HER2 pharmDx™ products have helped many women with
cancer by determining the right treatment for their disease. This latest
addition to our pharmDx™ portfolio of products supports Dako's mission
fight cancer by assisting pathologists in generating even more accurate,
objective and reproducible diagnostic results to the benefit of cancer
patients," says Lars Holmkvist, CEO of Dako.
A recent study comprising 365 breast cancer patients showed 98.3 and 97.7
percent concordance between results obtained with HER2 CISH pharmDx™ and
FDA-approved HER2 FISH tests. This is well over the threshold of 95 percent
recommended by the American Society of Clinical Oncology (ASCO) and the
of American Pathologists (CAP).
HER2 CISH pharmDx™ Kit was CE-IVD marked in June 2010. The product has
received FDA's approval and will be available to US customers as of
About HER2 CISH pharmDx™ Kit
HER2 CISH pharmDx™ Kit is a dual color chromogenic assay designed to
quantitatively determine HER2 gene amplifications in breast cancer tissue
specimens, using a bright field microscope for the HER2 scoring. In a
patients (20-25%) with breast cancer, the HER2 gene is amplified. HER2 CISH
pharmDx™ Kit is indicated as an aid in the assessment of patients for
Herceptin® treatment is being considered.
Herceptin® was developed to specifically target HER2-positive breast
Demonstration of high HER2 overexpression or gene amplification is
treatment with Herceptin®. Clinical studies have shown that breast
patients whose tumors have high HER2 receptor overexpression and/or
amplification benefit the most from Herceptin®.
About pharmacodiagnostics testing and personalized medicine
Pharmacodiagnostic testing is performed in order to aid in the selection of
patients for a treatment. This testing is a prerequisite for the
of personalized medicine where identification of the individual's
characteristics makes it possible to determine whether the patient will
to a specific drug treatment or not.
Dako, based in Denmark, is a global leader in tissue-based cancer
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make precise diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1000 people and being present in more than 80 countries, Dako covers
all of the anatomic pathology markets globally. Dako is owned by a private
equity fund EQT.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE